Trial Profile
A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a alpha1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Silodosin (Primary)
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- Acronyms STRONG
- Sponsors JW Pharmaceutical
- 28 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Dec 2010 New trial record